honglouwawa/iStock through Getty Photos
Whereas Eli Lilly missed on each the highest and backside traces in its Q3 monetary outcomes, a have a look at its gross sales figures — and particularly gross sales progress — would make many different pharmaceutical firms jealous.
Pushed by robust income progress
